NCT04435015 - The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular Complications | Biotech Hunter

Timeline

Start Date

November 30, 2021

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2021

Conditions

CoagulopathyCardiovascular ComplicationCOVID-19

Interventions

DRUG

Camostat Mesylate

Participants will be given Camostat mesylate three times daily.

DRUG

Microcrystalline Cellulose, NF

Participants will be given Microcrystalline Cellulose (placebo) three times daily.